Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2021-08-16 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' special statement and independent opinions regarding specific matters discussed at the 22nd meeting of the 8th board of directors of Shenzhen Haiwang Bioengineering Co., Ltd. It includes opinions on the company's 2021 half-year external guarantees and fund occupation, appointment of vice presidents, and senior management remuneration standards. The document references compliance with regulatory guidelines and company articles but does not contain full financial statements or detailed financial performance data. It is a governance-related document focusing on board and management matters rather than a full annual or interim report, audit report, or earnings release. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1233 characters), and it is not merely an announcement or certification but a substantive opinion from independent directors on board-related issues.
2021-08-16 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at a board meeting of Shenzhen Haiwang Bioengineering Co., Ltd. It includes approval of the 2021 semi-annual report and its summary, appointment of two vice presidents, and approval of senior management remuneration standards. The document does not contain the actual semi-annual financial report or detailed financial data but refers to the report being published elsewhere. It also includes detailed biographical information about the appointed executives. This type of document is an announcement of board/management changes and related resolutions rather than the report itself. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short (1905 characters), and it is not the full semi-annual report (which would be an Interim/Quarterly Report IR).
2021-08-16 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2021 年半年度报告摘要" which translates to "2021 Semi-Annual Report Summary." It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also includes shareholder information and important company events during the reporting period. The document is about 4050 characters long, which is relatively short but contains substantive financial data and analysis for a half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains actual financial statements and substantive financial data. It is not merely an announcement or a summary without data, so it should not be classified as a Report Publication Announcement (RPA). Therefore, the correct classification is IR. H1 2021
2021-08-16 Chinese
第八届董事局第二十一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Shenzhen Haier Bioengineering Co., Ltd. It details the meeting date, voting results, and specific agenda items such as extending the validity of a non-public stock issuance resolution and authorizations related to it. It also mentions the need to submit certain proposals to the shareholders' meeting. The document does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1599 characters), and it is not an announcement of a report publication but a substantive announcement of board decisions.
2021-08-02 Chinese
关于召开2021年第二次临时股东大会通知的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2021 second extraordinary general meeting of shareholders for Shenzhen Haiwang Bioengineering Co., Ltd. It includes information about the meeting date, voting procedures (including online voting), agenda items, proposal codes, registration methods, and proxy authorization forms. There is no financial data or report content, but rather an announcement and instructions related to a shareholders' meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document length is 3627 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, the correct classification is PSI with high confidence.
2021-08-02 Chinese
独立董事关于第八届董事局第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion regarding the extension of the validity period of a shareholders' meeting resolution on a non-public stock issuance and the authorization period. It references relevant laws and company articles, and it is a formal opinion rather than a full report or announcement of financial results. The content focuses on governance and compliance related to a specific board meeting matter. It is not a full annual or interim report, nor an earnings release or capital update. It is also not a simple announcement of a report publication. The document fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent director opinions on corporate governance issues.
2021-08-02 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.